AMSTERDAM (MedPage Today) — Treatment with daclizumab cut annualized relapse rates in half among patients with early relapsing-remitting multiple sclerosis, according to the results of a placebo-controlled trial.
http://www.medpagetoday.com/MeetingCoverage/ECTRIMS/29187
Sent with MobileRSS for iPhone
Júlio Leonardo B. Pereira
http://lattes.cnpq.br/7687651239699170
http://www.neurocirurgiabr.orghttp://www.neurocancer.com
